Partner CE Session: PCEC: Optimizing T2D Outcomes with GLP-1 Centered Treatment
Tuesday, December 8, 2026, – (America/New_York)
Partner CE Program
Participants in this presentation should be able to…
Incorporate cardio-kidney-metabolic risk reduction principles into T2D management by identifying patients who may benefit from GLP-1 RA-based therapy beyond glycemic control.
Differentiate current and emerging GLP-1 RA-based therapies by mechanism of action, route of administration, dosing/titration considerations, glycemic and extra-glycemic effects, and safety/tolerability profile to inform personalized treatment selection.
Implement practical strategies to initiate, titrate, and sustain GLP-1 RA-based treatment in primary care, including proactive adverse effect management, patient counseling, shared decision-making, and navigation of access barriers.
Speakers
-
MSN, CRNP, ANP-BC, BC-ADM, FAANP